Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2929Neoplasms 2624Lung Neoplasms 1366Colorectal Neoplasms 1328Prostatic Neoplasms 1214Carcinoma, Non-Small-Cell Lung 1079Carcinoma, Hepatocellular 782Stomach Neoplasms 720Pancreatic Neoplasms 701Ovarian Neoplasms 586Colonic Neoplasms 533Uterine Cervical Neoplasms 497Head and Neck Neoplasms 495Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 404Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 397Urinary Bladder Neoplasms 386Leukemia, Myeloid, Acute 385Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 312Recurrence 298Disease 272

Interventions

lorlatinib 1ceritinib 1brigatinib 1alectinib 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × ALK-positive NSCLC × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡